- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT06688084
Факторы патогенности Staphylococcus Pettenbergeri при ранах стоп и остеитах у больных сахарным диабетом (PETTENK-OS)
Оценка факторов патогенности Staphylococcus Pettenchoferi при ранах стоп и остеитах у больных сахарным диабетом. Исследование PETTENK-OS
Gram-positive cocci, particularly Staphylococcus aureus and coagulase-negative staphylococci (SCoN), are the bacteria most frequently isolated from diabetic foot ulcers. Although studies have been carried out on the role of S. aureus in the unfavorable evolution of these wounds, no studies have focused on the role of SCoN. Of the fifty or so SCoN species, not all have the same virulence potential. The role of Staphylococcus pettenkoferi is unknown, yet this bacterium is the 7th most frequently identified in diabetic foot ulcers, suggesting that it may also be involved in the pathophysiology of these infections. At Nîmes University Hospital, this bacterium is mainly identified in samples from diabetic foot ulcers or osteitis in our laboratory and 80% of the bacteria present are in biofilms.It is essential to understand the mechanisms governing these bacterial interactions and establish the true pathogenic potential of these bacteria. Recently, the Nîmes team showed that a strain of S. pettenkoferi (SP165) isolated from foot osteitis in a diabetic patient had real virulence potential. SP165 could not only produce biofilm, but could also survive in human blood, human keratinocytes and murine and human macrophages. It also caused significant embryonic mortality in a zebrafish model. A second study of 29 isolates from Nîmes University Hospital subsequently demonstrated that there were two predominant clones with different virulences. Three biofilm production profiles (rapidly and highly biofilm-producing, slowly biofilm-producing and non-biofilm-producing) and two zebrafish profiles (highly and moderately lethal) were reported by phenotypic and genomic analyses on this panel of strains. Genes for resistance, virulence and biofilm production were also found on their genomes.
Обзор исследования
Статус
Условия
Вмешательство/лечение
- Другой: Molecular epidemiology of the collection
- Другой: Study of the resistome of the S. pettenkoferi population
- Другой: Study of the virulome of the S. pettenkoferi population
- Другой: Study of the resistance profiles of all S. pettenkoferi isolates
- Другой: Selection of strains for in-depth phenotypic study
- Другой: Selection of strains (n=3) for the virulence study
Подробное описание
Gram-positive cocci, in particular Staphylococcus aureus and coagulase-negative staphylococci (SCoN), are the bacteria most frequently isolated from diabetic foot ulcers. While studies have been carried out on the role of S. aureus in the unfavorable evolution of these wounds, no study has focused on the role of SCoN. Of the fifty or so SCoN species, not all have the same virulence potential. The role of Staphylococcus pettenkoferi is not known. Yet this bacterium is the 7th most frequently identified in diabetic foot ulcers, suggesting that it may also be involved in the pathophysiology of these infections. In the work of Loetsche et al. a study of the microbiome of 349 diabetic foot ulcer samples by targeted 16S rDNA sequencing showed that the genus Staphylococcus was the most abundant, with a relative abundance of 22.8%, including 13.3% S. aureus and 5.3% S. pettenkoferi.
At Nîmes University Hospital, this bacterium is mainly identified in samples from diabetic foot ulcers or osteitis in our laboratory (89 isolations of S. pettenkoferi from diabetic foot ulcer samples out of 167 isolations made of this bacterium between 2018 and 2022).The difficulty of managing chronic wounds also lies in the fact that almost 80% of the bacteria present are in biofilms. It has also been established that the environment in which bacteria are found, and in particular the interactions they establish between themselves, play a significant role in delayed wound healing. It is therefore essential to understand the mechanisms governing these bacterial interactions and to establish the true pathogenic potential of these bacteria.
Recently, our team demonstrated that a strain of S. pettenkoferi (SP165) isolated from foot osteitis in a diabetic patient had real virulence potential. As well as being able to produce biofilm, SP165 was able to survive in human blood, human keratinocytes and murine and human macrophages. It also demonstrated its virulence by causing significant embryonic mortality in the zebrafish model.
A second study of 29 isolates from Nîmes University Hospital subsequently demonstrated the existence of two predominant clones with different virulences.
Three biofilm production profiles (rapidly and highly biofilm-producing, slowly biofilm-producing and non-biofilm-producing) and two zebrafish virulence profiles (highly and moderately lethal) were reported by phenotypic and genomic analyses on this panel of strains. Genes for resistance, virulence and biofilm production were also found on their genomes.
Тип исследования
Регистрация (Действительный)
Контакты и местонахождение
Места учебы
-
-
Gard
-
Nîmes, Gard, Франция, 30029
- Nîmes University Hospital
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
- Ребенок
- Взрослый
- Пожилой взрослый
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
The collection of strains at the Nîmes University Hospital site from 9 European laboratories collected between 2015 and 2023 for a total of 108 months was carried out between November 2021 and August 2023.
Описание
Inclusion Criteria:
- Not applicable for this research on a ready-constituted collection of strains of Staphylococcus pettenkoferi
Exclusion Criteria:
- Not applicable for this research on a ready-constituted collection of strains of Staphylococcus pettenkoferi
Учебный план
Как устроено исследование?
Детали дизайна
- Наблюдательные модели: COHORT
- Временные перспективы: OTHER
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Genetic diversity of Staphyloccocus pettenkoferi strains isolated from osteitis and non-diabetic wounds, blood cultures and nasal carriage.
Временное ограничение: Day 0 to 3 months
|
Number of clades estimated via typing by complete sequencing of the bacterial genomes of all S. pettenkoferi strains and analysis of phylogenetic distances (whole genome and core genome single nucleotide polymorphisms). |
Day 0 to 3 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Genetic diversity of Staphyloccocus pettenkoferi strains isolated from osteitis and non-diabetic wounds, blood cultures and nasal carriage.
Временное ограничение: 3 - 6 months
|
Number of clades estimated via typing by complete sequencing of the bacterial genomes of all Staphylococcus pettenkoferi strains and analysis of phylogenetic distances. |
3 - 6 months
|
|
Resistome in the strain population according to sample origin:osteitis
Временное ограничение: 3 - 6 months
|
The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Resistome in the strain population according to sample origin: non-diabetic wounds
Временное ограничение: 3 - 6 months
|
The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Resistome in the strain population according to sample origin: diabetic wounds
Временное ограничение: 3 - 6 months
|
The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Resistome in the strain population according to sample origin: blood cultures
Временное ограничение: 3 - 6 months
|
The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Resistome in the strain population according to sample origin: nasal carriage
Временное ограничение: 3 - 6 months
|
The presence of antibiotic resistance genes (resistome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Virulome in the strain population according to sample origin: osteitis
Временное ограничение: 3 - 6 months
|
The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Virulome in the strain population according to sample origin: non-diabetic wounds
Временное ограничение: 3 - 6 months
|
The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Virulome in the strain population according to sample origin: diabetic wounds
Временное ограничение: 3 - 6 months
|
The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Virulome in the strain population according to sample origin: blood cultures
Временное ограничение: 3 - 6 months
|
The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Virulome in the strain population according to sample origin: nasal carriage
Временное ограничение: 3 - 6 months
|
The presence of virulence genes (virulome) will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Plasmids inthe strain population and according to sample origin: osteitis
Временное ограничение: 3 - 6 months
|
The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Plasmids inthe strain population and according to sample origin: non-diabetic wounds
Временное ограничение: 3 - 6 months
|
The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Plasmids inthe strain population and according to sample origin: diabetic wounds
Временное ограничение: 3 - 6 months
|
The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Plasmids inthe strain population and according to sample origin: blood cultures
Временное ограничение: 3 - 6 months
|
The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Plasmids inthe strain population and according to sample origin: nasal carriage
Временное ограничение: 3 - 6 months
|
The presence of plasmids will be identified by bioinformatics analysis of sequenced bacterial genomes. |
3 - 6 months
|
|
Phenotypic resistance profiles in the population in a subsample of 85 strains
Временное ограничение: 6 - 14 months
|
The minimum inhibitory concentration for a series of antibiotics will be recorded (antibiograms of isolates).These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. |
6 - 14 months
|
|
Phenotypic resistance profiles in the population and according to sample origin: osteitis
Временное ограничение: 6 - 14 months
|
Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. |
6 - 14 months
|
|
Phenotypic resistance profiles in the population and according to sample origin: non-diabetic wounds
Временное ограничение: 6 - 14 months
|
Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. |
6 - 14 months
|
|
Phenotypic resistance profiles in the population and according to sample origin: diabetic wounds
Временное ограничение: 6 - 14 months
|
Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. |
6 - 14 months
|
|
Phenotypic resistance profiles in the population and according to sample origin: blood cultures
Временное ограничение: 6 - 14 months
|
Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. |
6 - 14 months
|
|
Phenotypic resistance profiles in the population and according to sample origin: nasal carriage
Временное ограничение: 6 - 14 months
|
Minimum inhibitory concentration for a series of antibiotics (antibiograms of isolates). These antibiograms will be established on newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. |
6 - 14 months
|
|
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: osteitis
Временное ограничение: 6 - 14 months
|
Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm |
6 - 14 months
|
|
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: non-diabetic wounds
Временное ограничение: 6 - 14 months
|
Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm |
6 - 14 months
|
|
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: diabetic wounds
Временное ограничение: 6 - 14 months
|
Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm |
6 - 14 months
|
|
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: blood cultures
Временное ограничение: 6 - 14 months
|
Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm |
6 - 14 months
|
|
Amount of biofilm formation in the absence and presence of antibiotics in a selection (85 sub-samples) of S. pettenkoferi strains according to sample origine: nasal carriage
Временное ограничение: 6 - 14 months
|
Biofilm formation index in the presence/absence of a series of antibiotics (antibiograms of isolates). These antibiotics will be newly-marketed or current molecules such as Ceftarolin, Ceftobiprol, Dalbavancin, Delafloxacin, Tedizolid and Oritavancin. Results recorded on a scale ranging from 0 = biofilm and 12 = no biofilm |
6 - 14 months
|
|
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: osteitis
Временное ограничение: 6 - 14 months
|
Bacterial growth curve by measuring absorbance on bacterial culture over time. |
6 - 14 months
|
|
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: non-diabetic wounds
Временное ограничение: 6 - 14 months
|
Bacterial growth curve by measuring absorbance on bacterial culture over time. |
6 - 14 months
|
|
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: diabetic wounds
Временное ограничение: 6 - 14 months
|
Bacterial growth curve by measuring absorbance on bacterial culture over time. |
6 - 14 months
|
|
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: blood cultures
Временное ограничение: 6 - 14 months
|
Bacterial growth curve by measuring absorbance on bacterial culture over time. |
6 - 14 months
|
|
Bacterial growth rate according to sample origin in a sub-sample of 20 strains: nasal carriage
Временное ограничение: 6 - 14 months
|
Bacterial growth curve by measuring absorbance on bacterial culture over time. |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: osteitis
Временное ограничение: 6 - 14 months
|
The rate of internalisation and release of LDH (a sign of cellular toxicity of the bacterial isolate) in an in vitro osteoblast cell culture model (MC3T3-E1) |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: intracellular bacterial multiplication of S. pettenkoferi strains from osteitis
Временное ограничение: 6 - 14 months
|
The amount of intracellular bacterial multiplication will be assessed in an in vitro macrophage cell culture model (RAW 264.7). |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: diabetic wounds
Временное ограничение: 6 - 14 months
|
The rate of internalisation and release of LDH (a sign of cellular toxicity of the bacterial isolate) in an in vitro osteoblast cell culture model (MC3T3-E1) |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: intracellular bacterial multiplication of S. pettenkoferi strains from diabetic wounds
Временное ограничение: 6 - 14 months
|
The amount of intracellular bacterial multiplication will be assessed in an in vitro macrophage cell culture model (RAW 264.7). |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: blood cultures
Временное ограничение: 6 - 14 months
|
The rate of internalisation and release of LDH (a sign of cellular toxicity of the bacterial isolate) in an in vitro osteoblast cell culture model (MC3T3-E1) |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains:intracellular bacterial multiplication of S. pettenkoferi strains from blood cultures
Временное ограничение: 6 - 14 months
|
The amount of intracellular bacterial multiplication will be assessed in an in vitro macrophage cell culture model (RAW 264.7). |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: nasal carriage
Временное ограничение: 6 - 14 months
|
The rate of internalisation and release of LDH (a sign of cellular toxicity of the bacterial isolate) in an in vitro osteoblast cell culture model (MC3T3-E1) |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains:intracellular bacterial multiplication of S. pettenkoferi strains from nasal carriage
Временное ограничение: 6 - 14 months
|
The amount of intracellular bacterial multiplication will be assessed in an in vitro macrophage cell culture model (RAW 264.7). |
6 - 14 months
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from osteitis
Временное ограничение: Up to 48 hours
|
Survival curve at 48 hours |
Up to 48 hours
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from non-diabetic wounds
Временное ограничение: Up to 48 hours
|
Survival curve at 48 hours |
Up to 48 hours
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from diabetic wounds
Временное ограничение: Up to 48 hours
|
Survival curve at 48 hours |
Up to 48 hours
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from blood cultures
Временное ограничение: Up to 48 hours
|
Survival curve at 48 hours |
Up to 48 hours
|
|
Virulence profiles according to sample origin in a sub-sample of 3 strains: survival time of diabetic zebrafish immersed in S. pettenkoferi strains from nasal carriage
Временное ограничение: Up to 48 hours
|
Survival curve at 48 hours |
Up to 48 hours
|
Соавторы и исследователи
Соавторы
Следователи
- Главный следователь: Chloé MAGNAN, Dr., Nîmes University Hospital, FRANCE
Публикации и полезные ссылки
Общие публикации
- Magnan C, Curtil-Dit-Galin M, Morsli M, Cattoir V, Piau-Couapel C, Soderquist B, Kahl BC, Denis O, Rwayane K, Corvec S, Francois P, Salipante F, Pantel A, Dunyach-Remy C, Laurent F, Lavigne JP; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS). Staphylococcus pettenkoferi: an underrecognized species with clinically relevant antimicrobial resistance. A comprehensive genomic European study. Emerg Microbes Infect. 2026 Dec;15(1):2724635. doi: 10.1080/22221751.2026.2724635. Epub 2026 Sep 16.
- Magnan C, Plumet L, Morsli M, Dunyach-Remy C, Pouget C, Sotto A, Molle V, Lavigne J-P. A narrative review of coagulase-negative staphylococci in diabetic foot infections. Clin Microbiol Rev. 2025 Dec 11;38(4):e0012125. doi: 10.1128/cmr.00121-25. Epub 2025 Nov 4.
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- Заболевания эндокринной системы
- Заболевания костей
- Заболевания опорно-двигательного аппарата
- Сосудистые заболевания
- Сердечно-сосудистые заболевания
- Метаболические заболевания
- Нарушения метаболизма глюкозы
- Диабетические ангиопатии
- Осложнения диабета
- Кожные заболевания
- Язва кожи
- Язва на ноге
- Диабетические невропатии
- Язва стопы
- Пищевые и метаболические заболевания
- Заболевания кожи и соединительной ткани
- Сахарный диабет
- Инфекции
- Диабетическая стопа
- Остит
Другие идентификационные номера исследования
- NIMAO/2023-2/CM-01
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .